

DECLARATION OF INTERESTS

Y.G. is a consultant for Oriel Research Therapeutics. T.M.Y. is a co-founder, stockholder, and on the board of directors of DESTROKE, Inc., an early-stage start-up developing mobile technology for automated clinical stroke detection. J.L.J. has received consulting fees from Scorpion Therapeutics and Volastra Therapeutics. Y.E.M. is a consultant for ForseeGenomics and is also an inventor on patent applications filed by the Broad Institute related to MSMuTect, MSMutSig, and MSIDetect. N.J.H. is a consultant for MorphoSys. F.A. is an inventor on a patent application related to SignatureAnalyzer-GPU and has been an employee of Illumina, Inc., since 8 November 2021. L.C.C. is a founder and member of the board of directors of Agios Pharmaceuticals and is a founder of Petra Pharmaceuticals. L.C.C. is an inventor on patents (pending) for Combination Therapy for PI3K-associated Disease or Disorder, and The Identification of Therapeutic Interventions to Improve Response to PI3K Inhibitors for Cancer Treatment. L.C.C. is a co-founder and shareholder in Faeth Therapeutics. G.G. receives research funds from IBM, Pharmacyclics, and Ultima Genomics, and is also an inventor on patent applications filed by the Broad Institute related to MSMuTect, MSMutSig, POLYSOLVER, SignatureAnalyzer-GPU, MSIDetect, and MinimuMM-Seq. He is also a founder, consultant, and privately held equity in Scorpion Therapeutics.

Received: July 12, 2022

Revised: January 6, 2023

Accepted: July 10, 2023

Published: August 14, 2023

REFERENCES

- Ding, L., Bailey, M.H., Porta-Pardo, E., Thorsson, V., Colaprico, A., Bertrand, D., Gibbs, D.L., Weerasinghe, A., Huang, K.-L., Tokheim, C., et al. (2018). Perspective on oncogenic processes at the end of the beginning of cancer genomics. *Cell* 173, 305–320.e10. <https://doi.org/10.1016/j.cell.2018.03.033>.
- Doroshov, D.B., and Doroshov, J.H. (2020). Genomics and the history of precision oncology. *Surg. Oncol. Clin. N. Am.* 29, 35–49. <https://doi.org/10.1016/j.soc.2019.08.003>.
- Rodriguez, H., Zenklusen, J.C., Staudt, L.M., Doroshov, J.H., and Lowy, D.R. (2021). The next horizon in precision oncology: proteogenomics to inform cancer diagnosis and treatment. *Cell* 184, 1661–1670. <https://doi.org/10.1016/j.cell.2021.02.055>.
- Wang, L.-B., Karpova, A., Gritsenko, M.A., Kyle, J.E., Cao, S., Li, Y., Rykunov, D., Colaprico, A., Rothstein, J.H., Hong, R., et al. (2021). Proteogenomic and metabolomic characterization of human glioblastoma. *Cancer Cell* 39, 509–528.e20. <https://doi.org/10.1016/j.ccell.2021.01.006>.
- Huang, C., Chen, L., Savage, S.R., Eguez, R.V., Dou, Y., Li, Y., da Veiga Leprevost, F., Jaehnig, E.J., Lei, J.T., Wen, B., et al. (2021). Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. *Cancer Cell* 39, 361–379.e16. <https://doi.org/10.1016/j.ccell.2020.12.007>.
- Gillette, M.A., Satpathy, S., Cao, S., Dhanasekaran, S.M., Vasaikar, S.V., Krug, K., Petralia, F., Li, Y., Liang, W.-W., Reva, B., et al. (2020). Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma. *Cell* 182, 200–225.e35. <https://doi.org/10.1016/j.cell.2020.06.013>.
- Satpathy, S., Krug, K., Jean Beltran, P.M., Savage, S.R., Petralia, F., Kumar-Sinha, C., Dou, Y., Reva, B., Kane, M.H., Avanesian, S.C., et al. (2021). A proteogenomic portrait of lung squamous cell carcinoma. *Cell* 184, 4348–4371.e40. <https://doi.org/10.1016/j.cell.2021.07.016>.
- Krug, K., Jaehnig, E.J., Satpathy, S., Blumenberg, L., Karpova, A., Anurag, M., Miles, G., Mertins, P., Geffen, Y., Tang, L.C., et al. (2020). Proteogenomic landscape of breast cancer tumorigenesis and targeted therapy. *Cell* 183, 1436–1456.e31. <https://doi.org/10.1016/j.cell.2020.10.036>.
- Cao, L., Huang, C., Cui Zhou, D., Hu, Y., Lih, T.M., Savage, S.R., Krug, K., Clark, D.J., Schnaubelt, M., Chen, L., et al. (2021). Proteogenomic characterization of pancreatic ductal adenocarcinoma. *Cell* 184, 5031–5052.e26. <https://doi.org/10.1016/j.cell.2021.08.023>.
- Clark, D.J., Dhanasekaran, S.M., Petralia, F., Pan, J., Song, X., Hu, Y., da Veiga Leprevost, F., Reva, B., Lih, T.-S.M., Chang, H.-Y., et al. (2019). Integrated proteogenomic characterization of clear cell renal cell carcinoma. *Cell* 179, 964–983.e31. <https://doi.org/10.1016/j.cell.2019.10.007>.
- McDermott, J.E., Arshad, O.A., Petyuk, V.A., Fu, Y., Gritsenko, M.A., Clauss, T.R., Moore, R.J., Schepmoes, A.A., Zhao, R., Monroe, M.E., et al. (2020). Proteogenomic characterization of ovarian HGSC implicates mitotic kinases, replication stress in observed chromosomal instability. *Cell Rep. Med.* 1, 100004. <https://doi.org/10.1016/j.xcrm.2020.100004>.
- Dou, Y., Kawaler, E.A., Cui Zhou, D., Gritsenko, M.A., Huang, C., Blumenberg, L., Karpova, A., Petyuk, V.A., Savage, S.R., Satpathy, S., et al. (2020). Proteogenomic characterization of endometrial carcinoma. *Cell* 180, 729–748.e26. <https://doi.org/10.1016/j.cell.2020.01.026>.
- Vasaikar, S., Huang, C., Wang, X., Petyuk, V.A., Savage, S.R., Wen, B., Dou, Y., Zhang, Y., Shi, Z., Arshad, O.A., et al. (2019). Proteogenomic analysis of human colon cancer reveals new therapeutic opportunities. *Cell* 177, 1035–1049.e19. <https://doi.org/10.1016/j.cell.2019.03.030>.
- Mani, D.R., Krug, K., Zhang, B., Satpathy, S., Clauser, K.R., Ding, L., Ellis, M., Gillette, M.A., and Carr, S.A. (2022). Cancer proteogenomics: current impact and future prospects. *Nat. Rev. Cancer* 22, 298–313. <https://doi.org/10.1038/s41568-022-00446-5>.
- Deribe, Y.L., Pawson, T., and Dikic, I. (2010). Post-translational modifications in signal integration. *Nat. Struct. Mol. Biol.* 17, 666–672. <https://doi.org/10.1038/nsmb.1842>.
- Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W.K., Luna, A., La, K.C., Dimitriadou, S., Liu, D.L., Kantheti, H.S., Saghafein, S., et al. (2018). Oncogenic signaling pathways in The Cancer Genome Atlas. *Cell* 173, 321–337.e10. <https://doi.org/10.1016/j.cell.2018.03.035>.
- Bailey, M.H., Tokheim, C., Porta-Pardo, E., SenGupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M.C., Kim, J., Reardon, B., et al. (2018). Comprehensive characterization of cancer driver genes and mutations. *Cell* 173, 371–385.e18. <https://doi.org/10.1016/j.cell.2018.02.060>.
- Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. *Cell* 144, 646–674. <https://doi.org/10.1016/j.cell.2011.02.013>.
- Narita, T., Weinert, B.T., and Choudhary, C. (2019). Functions and mechanisms of non-histone protein acetylation. *Nat. Rev. Mol. Cell Biol.* 20, 156–174. <https://doi.org/10.1038/s41580-018-0081-3>.
- Biswas, S.K. (2015). Metabolic reprogramming of immune cells in cancer progression. *Immunity* 43, 435–449. <https://doi.org/10.1016/j.immuni.2015.09.001>.
- Yu, W., Lei, Q., Yang, L., Qin, G., Liu, S., Wang, D., Ping, Y., and Zhang, Y. (2021). Contradictory roles of lipid metabolism in immune response within the tumor microenvironment. *J. Hematol. Oncol.* 14, 187. <https://doi.org/10.1186/s13045-021-01200-4>.
- Rohatgi, N., Ghoshdastider, U., Baruah, P., Kulshrestha, T., and Skanderup, A.J. (2022). A pan-cancer metabolic atlas of the tumor microenvironment. *Cell Rep.* 39, 110800. <https://doi.org/10.1016/j.celrep.2022.110800>.
- Manzo, T., Prentice, B.M., Anderson, K.G., Raman, A., Schalck, A., Co-dreanu, G.S., Nava Lauson, C.B., Tiberti, S., Raimondi, A., Jones, M.A., et al. (2020). Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells. *J. Exp. Med.* 217, e20191920. <https://doi.org/10.1084/jem.20191920>.
- Peleg, S., Feller, C., Ladurner, A.G., and Imhof, A. (2016). The metabolic impact on histone acetylation and transcription in ageing. *Trends Biochem. Sci.* 41, 700–711. <https://doi.org/10.1016/j.tibs.2016.05.008>.